Concomitant driver gene mutations in EGFR and ALK have been detected in 1.3%‐15.4% of the patients with non‐small cell lung cancer (NSCLC), depending on the method used.8, 9 Among the patients harboring EGFR/ALK coalterations, some responded to treatment with an EGFR‐TKI (ie, gefitinib, erlotinib, icotinib, or afatinib),8, 10, 11, 12, 13 while others responded to treatment with an ALK‐TKI (crizotinib) 9, 13 or both.14, 15 To the best of our knowledge, there is currently no consensus for the optimal management for these patients. The gene discussed is EGFR; the disease is lung cancer.